TLN-372 in Advanced KRAS Mutant Solid Tumors

Recruiting

Phase 1

TLN-372TLN-372 in Advanced KRAS Mutant Solid Tumors

Sponsor:

Treeline Biosciences, Inc.

Code:

NCT07204340

Conditions

KRAS Mutant Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TLN-372

TLN-372 in combination with cetuximab

TLN-372 in combination with pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by Treeline Biosciences, Inc. on 2025-10-02.